Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Leukemia, B-Cell 4Multiple Myeloma 3Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1DLBCL 1

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × acalabrutinib × Clear all
NCT02362035 2026-05-13

KEYNOTE145

Acerta Pharma BV

Phase 1/2 Completed
161 enrolled 29 charts
LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02328014 2025-12-09

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Acerta Pharma BV

Phase 1/2 Completed
40 enrolled 12 charts
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02211014 2020-07-31

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Acerta Pharma BV

Phase 1 Completed
27 enrolled 13 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡